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A recent study by the Medical Research Council (MRC)
Perinatal Mortality Research Unit at Tygerberg Hospital found
that 39% of pregnant women smoked cigarettes.1 Smoking in
pregnancy is clearly recognised in the literature as an
important, dose-related, preventable risk factor for poor
perinatal outcome.2 A previous MRC finding that 47% of South
African coloured women smoke during pregnancy3 stands in
sharp contrast to the prevalence in developed countries, for
example 15.8% in the USA.4 In a developing country, where
poverty in itself increases perinatal mortality and morbidity,
this increase in cigarette smoking may have further negative
effects on perinatal outcome, despite efforts to optimise
antenatal care.
It is, therefore, of concern that despite current knowledge of
the harmful effects of smoking in pregnancy, such a large
percentage of pregnant women at Tygerberg Hospital are
smokers. We wondered to what extent pregnant patients at
Tygerberg Hospital are aware of the harmful effects of cigarette
smoking during pregnancy and after childbirth.
What was done
The study group consisted of 200 pregnant coloured women
attending the high-risk antenatal clinic (HRC) at Tygerberg
Hospital. Most of these mothers have had previous pregnancy
complications or losses, or suffered from a medical condition
that could complicate the pregnancy. For some patients, the
HRC served as a secondary clinic because they lived close to
the hospital.
Information was gathered over a period of 3 weeks in March
2000 by means of a self-completed questionnaire, which was
handed out in the HRC waiting area. 
Smokers were asked about their smoking habits and whether
they considered altering these habits during pregnancy.
Knowledge of smokers was tested with regard to the effects of
active maternal smoking and environmental tobacco smoke
(ETS) on pregnancy and infants. An enquiry was made into
breast-feeding intentions and willingness to expose infants to
active maternal smoking. Non-smokers were asked about
previous smoking habits, the smoke-free interval, motivation
for quitting, and whether they considered resuming smoking
after the delivery. There were further questions to non-smokers
regarding their knowledge of the effects of active maternal
smoking and ETS on pregnancy. An enquiry was made into
exposure of non-smokers to ETS.
What was found
Of the 200 respondents, only 57.5% did not smoke and 42.5%
smoked. With regard to awareness of the effects of smoking in
pregnancy, 8.2% of smokers thought it was harmless and 11.8%
indicated knowledge of nonspecific effects. Most smokers
(77.6%) knew about one or more of the following specific
dangers: disturbed growth parameters (62%), respiratory risk
(45%) and a threat to general health (23%). The remaining 2.4%
of smokers left the question unanswered.
Sixty-seven per cent of the non-smokers had never smoked
previously.  Of the 33% of ex-smokers, 34.2% had stopped
smoking on falling pregnant, while 60.5% had quit before
falling pregnant. The remaining 5.3% of ex-smokers left the
question unanswered. Only 20% of non-smokers were not
exposed to ETS. The specific knowledge of smokers and non-
smokers is shown in Table I.
Recommendations
In the quest for optimal perinatal outcome it is essential to
convey current scientific knowledge to the target group of
pregnant mothers. This could be achieved effectively at clinic
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Table I. Specific knowledge of effects of active smoking on
pregnancy (%)
Specific knowledge                            Smokers         Non-smokers
Health risk 23 25
Respiratory risk 45 45
Neurological side-effects 12 5
Abnormal development 13 4
Pregnancy loss 10 7
Preterm labour 12 4
Disturbed growth parameters 62 39
Cancer 9 4
Future problems 3 6
Cardiovascular risk 0 6
Maternal disease (e.g. respiratory) 7 0    
At the time of the study Dr J E Viljoen was a registrar in the
Department of Obstetrics and Gynaecology, Stellenbosch
University.  Professor H J Odendaal is head of the Department.
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Pfizer South Africa announced on 13 April 2005 that the
company would suspend the sale of the oral Cox-2 inhibitor
Bextra with immediate effect. The suspension is voluntary and
at the request of the Medicines Control Council.
This suspension of sales does not stem from any new
scientific information, but is a direct result of the request by the
Council. While Pfizer respectfully disagrees with the Council
decision and believes that Bextra is a valuable treatment
alternative for the relief of short-term postoperative pain and
primary dysmenorrhoea, the company will comply with the
request pending investigation of the entire NSAID and Cox-2
class of medicines. 
The Medicines Control Council request for a voluntary
suspension follows a similar request from the US Food and
Drug Administration and various other regulatory bodies,
including the European Medicines Agency, EMEA. In coming to
their decision, the FDA considered that unproven
cardiovascular safety in long-term use, coupled with the
possibility of severe skin reactions, led to an unfavourable risk-
benefit profile. Bextra, which was launched in South Africa in
August 2004, is only indicated for the treatment of acute, mild
to moderate postoperative pain and primary dysmenorrhoea
and not for long-term use in rheumatoid or osteoarthritis, as in
the USA. Treatment typically runs for 5 days. 
To this end, the following advice is offered: 
Prescribers are advised not to initiate treatment in new
patients and physicians should consider whether patients
currently on Bextra should finish their current course of
treatment while being monitored or be switched immediately to
alternative therapeutic options. 
Pharmacists are advised not to dispense further prescriptions
for Bextra and to advise patients receiving Bextra to return to
their doctors to discuss alternative therapeutic options. In
addition, pharmacists are advised that stock will be withdrawn
from their sites, through a withdrawal notification procedure. 
Patients are advised to make an appointment with their
health care providers to discuss their current treatment with
Bextra and alternative treatment options. 
For further drug-related information, please call Pfizer on 
086 073 4937.
Pfizer withdraws Bextra in South Africa
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or hospital visits and antenatal consultations. Awareness
should be raised by means of pamphlets and posters
explaining the dangers of smoking in pregnancy, using
layman’s terms and illustrations. These could be made freely
available in waiting areas and consultation rooms.
On a personal level, the patient should be addressed in a
non-judgemental manner, taking into account her psychosocial
situation, e.g. social pressures, and the presence of spouse,
partner or family members who smoke. The aim should be to
enlighten the patient and her family and friends regarding the
importance of smoking cessation in pregnancy. 
An effective way to persuade smokers to quit in pregnancy
during a 5  - 15-minute consultation (Table II) has recently been
suggested.5
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Table II. Smoking cessation intervention for pregnant
patients
Consultation scheme
1. Ask Enquiring about smoking status
2. Advise Provide strong advice to quit, with 
personalised messages on benefits of 
quitting and the impact of smoking 
on the woman and fetus 
3. Assess Assess the willingness of the patient to quit 
within the next 30 days
4. Assist Suggest and encourage problem-solving 
methods
Provide social support
Arrange social support
Provide pregnancy-specific, self-help 
smoking cessation materials
5. Arrange Assess status in follow-up visits, 
encourage cessation if still smoking
308-311  5/6/05  12:36 PM  Page 310
